Homology medicines, inc. (FIXX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-115,395

-103,916

-98,535

-83,056

-69,212

-55,577

-48,696

-41,076

-34,653

-29,991

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

6,959

6,318

5,162

3,739

2,334

1,289

926

848

774

684

0

0

0

Amortization of right-of-use assets

0

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

9,275

7,635

6,154

4,887

3,486

2,623

1,828

1,167

629

277

0

0

0

Amortization of premium on short-term investments

1,385

1,871

2,801

2,900

2,127

1,589

0

0

0

-

-

-

-

Change in fair value associated with convertible preferred stock tranche liability

-

-

-

-

-

-

-

-

-

876

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

567

-2,759

-3,916

-3,102

-1,138

5,003

7,573

5,102

2,800

1,463

0

0

0

Accounts payable

474

-4,452

6,465

2,392

3,787

4,383

617

4,138

1,880

1,720

0

0

0

Accrued expenses and other liabilities

3,184

2,315

3,332

2,989

2,402

3,042

2,041

809

169

864

0

0

0

Deferred revenue

-680

-569

-785

-1,185

-1,519

-1,890

0

0

0

-

-

-

-

Deferred rent

-

-410

-3,861

-8,593

-10,195

-10,033

-6,968

-2,523

-1,219

-186

0

0

0

Operating lease liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-99,333

-91,358

-73,104

-61,312

-49,389

-42,562

-12,435

-4,191

-40

6,479

0

0

0

Purchases of short-term investments

-

286,391

270,257

291,033

311,200

245,328

0

0

0

-

-

-

-

Maturities of short-term investments

258,855

256,425

282,725

274,485

236,810

148,480

0

0

0

-

-

-

-

Purchases of property and equipment

13,400

21,833

34,038

37,140

34,370

24,939

9,345

4,820

2,144

1,958

0

0

0

Net cash provided by investing activities

43,531

-51,799

-21,570

-53,688

-108,760

-121,787

-211,893

-166,938

-74,037

-81,526

0

0

0

Cash flows from financing activities:
Proceeds from issuance of common stock pursuant to employee stock purchase plan

970

829

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock from option exercises

465

351

327

78

39

87

0

0

0

-

-

-

-

Payment of deferred offering costs

0

-

-

-

0

-

-

-

0

-

-

-

-

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash provided by financing activities

158,335

158,213

135,679

135,090

152,277

150,994

162,615

245,678

93,792

115,230

0

0

0

Net change in cash, cash equivalents and restricted cash

102,533

15,056

41,005

20,090

-5,872

-13,355

-61,712

74,548

19,714

40,183

0

0

0

Reclassification of liability for common stock vested

54

60

65

105

77

75

261

210

220

225

0

0

0

Property and equipment additions included in accounts payable

-4,414

455

338

10,023

14,374

9,127

9,500

250

-20

167

0

0

0

Property and equipment additions included in accrued expenses and other liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on available for sale securities, net

0

-

-

-

0

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

0

-

-

0

0

-

-

-

0

-

-

-

-